Some counterfeits contain bacteria and have high impurity levels or different chemical structures to FDA-approved medicines.

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

He continues: "Often they’re also low in calories so you eat fewer calories while still feeling satisfied. When you eat fibre ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Large employers could spend as much as an additional 7.8% in health costs next year, according to a Business Group on Health survey.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

A recent survey by Zimmer Biomet indicated that some obese patients may be eligible for surgery following weight loss due to the use of GLP-1 medications, but respondents did not feel that these ...

Here are five key takeaways: During the hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the high prices of drugs such as Ozempic and Wegovy to PBMs, arguing that "a high list price is ...